{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    35,
    36,
    37,
    38,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Ibrutinib",
        "type": {
          "id": "00f07e33-a182-47c0-9655-1a8f5233db88",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "f1089baf-81a4-4b3f-bf24-2ed3dc934b49",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "First-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton’s tyrosine kinase (BTK).",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "40455c44-bcd1-4f76-9b52-d4e888a45282",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "0d4a0e27-5563-43ff-b967-a1597e2e7488",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules for ibrutinib.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Bendamustine hydrochloride",
        "type": {
          "id": "9ee0af02-3777-40bd-854f-9db3927b805d",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "d1c9348e-6987-416e-8120-a003ba8b7fc5",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Antineoplastic alkylating agent used in combination with rituximab (BR regimen).",
        "productIds": [
          "prod_3"
        ],
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Rituximab",
        "type": {
          "id": "15e3fac8-53b2-47d0-beaa-36566550244b",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "0f15ccad-ef2a-41d2-890e-0f70c7d3befe",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "CD20-directed cytolytic antibody used in induction and maintenance phases.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Antimicrobial prophylaxis",
        "type": {
          "id": "230c15b0-c6f3-4a10-9458-d4ff3ae4f0a3",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "5177521b-5711-4671-93ec-9979f44e26b3",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted and should be considered for subjects at increased risk for opportunistic infections.",
        "administrationIds": [
          "admin_5"
        ]
      },
      {
        "id": "int_6",
        "name": "Anti-hormonal therapy",
        "type": {
          "id": "03ecbbea-0fc9-4ae2-8e0e-83ebcee436b8",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "56c69a47-643d-4e39-9827-2d56be309a9e",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted after discussion with the sponsor’s medical monitor."
      },
      {
        "id": "int_7",
        "name": "Warfarin",
        "type": {
          "id": "b3b8eaae-6ca3-4eb2-b74a-05af95908776",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "bef20ca3-3939-4587-b2fe-d94f5ebeb646",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited; other vitamin K antagonists are also prohibited."
      },
      {
        "id": "int_8",
        "name": "Fish oil and Vitamin E",
        "type": {
          "id": "7040ee0a-c0df-41da-b335-648700881aaf",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "5271cb00-ad54-4d51-8eec-fee0fa6be398",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Supplements that should be avoided due to bleeding risk."
      },
      {
        "id": "int_9",
        "name": "Strong or moderate CYP3A inhibitors",
        "type": {
          "id": "a588d4a0-a213-4a54-a3f9-a301f701a7db",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "f4d4e3de-3f3a-4929-bae1-633e0b955060",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Should be avoided; if required, ibrutinib dose must be reduced or withheld."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Ibrutinib capsules",
        "administrableDoseForm": {
          "id": "2cf82774-1344-468f-945d-01969dd74ec9",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "11c9d260-f917-4799-9aa6-27e9beb17312",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "d7eea9c6-f904-41a0-989a-f1c36a28d994",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "140 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Janssen Research & Development / Pharmacyclics LLC"
      },
      {
        "id": "prod_2",
        "name": "Bendamustine hydrochloride",
        "administrableDoseForm": {
          "id": "60640bf3-ce78-4f70-9eb7-383fd82dc45f",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "af192383-78e9-4569-b2d2-abed588b54f3",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "94a6cc91-bfe4-464e-b399-b35157c44d06",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Not specified"
      },
      {
        "id": "prod_3",
        "name": "Rituximab",
        "administrableDoseForm": {
          "id": "d1299aed-4fe1-4261-aac6-9fd2345b55af",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "55ef025c-f372-4e2d-848b-50b9757892bf",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "622a8cb1-259d-44eb-84b3-60836631db48",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_3"
        ],
        "manufacturer": "Not specified"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Ibrutinib 560 mg daily",
        "instanceType": "Administration",
        "dose": "560 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Daily and continuously until disease progression or unacceptable toxicity"
      },
      {
        "id": "admin_2",
        "name": "Bendamustine 90 mg/m2",
        "instanceType": "Administration",
        "dose": "90 mg/m2",
        "doseFrequency": "Days 1 and 2 of each 28-day cycle",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Maximum of 6 cycles"
      },
      {
        "id": "admin_3",
        "name": "Rituximab Induction",
        "instanceType": "Administration",
        "dose": "375 mg/m2",
        "doseFrequency": "Day 1 of each 28-day cycle",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Cycles 1 to 6"
      },
      {
        "id": "admin_4",
        "name": "Rituximab Maintenance",
        "instanceType": "Administration",
        "dose": "375 mg/m2",
        "doseFrequency": "Day 1 of every second cycle (even cycles)",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Maximum of 12 additional doses (up to Cycle 30)"
      },
      {
        "id": "admin_5",
        "name": "Ibrutinib Dose Reduction (Strong CYP3A Inhibitor)",
        "instanceType": "Administration",
        "dose": "140 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Duration of strong CYP3A inhibitor use"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Ibrutinib",
        "instanceType": "Substance",
        "description": "1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d] pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one"
      },
      {
        "id": "sub_2",
        "name": "Bendamustine hydrochloride",
        "instanceType": "Substance",
        "description": "Mechlorethamine derivative"
      },
      {
        "id": "sub_3",
        "name": "Rituximab",
        "instanceType": "Substance",
        "description": "Monoclonal antibody"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 9,
      "productCount": 3,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Ibrutinib",
        "role": "Investigational Product",
        "description": "First-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton’s tyrosine kinase (BTK)."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo capsules for ibrutinib."
      },
      {
        "name": "Bendamustine hydrochloride",
        "role": "Background Therapy",
        "description": "Antineoplastic alkylating agent used in combination with rituximab (BR regimen)."
      },
      {
        "name": "Rituximab",
        "role": "Background Therapy",
        "description": "CD20-directed cytolytic antibody used in induction and maintenance phases."
      },
      {
        "name": "Antimicrobial prophylaxis",
        "role": "Concomitant Medication",
        "description": "Permitted and should be considered for subjects at increased risk for opportunistic infections."
      },
      {
        "name": "Anti-hormonal therapy",
        "role": "Concomitant Medication",
        "description": "Permitted after discussion with the sponsor’s medical monitor."
      },
      {
        "name": "Warfarin",
        "role": "Concomitant Medication",
        "description": "Prohibited; other vitamin K antagonists are also prohibited."
      },
      {
        "name": "Fish oil and Vitamin E",
        "role": "Concomitant Medication",
        "description": "Supplements that should be avoided due to bleeding risk."
      },
      {
        "name": "Strong or moderate CYP3A inhibitors",
        "role": "Concomitant Medication",
        "description": "Should be avoided; if required, ibrutinib dose must be reduced or withheld."
      }
    ],
    "products": [
      {
        "name": "Ibrutinib capsules",
        "doseForm": "Capsule",
        "strength": "140 mg",
        "manufacturer": "Janssen Research & Development / Pharmacyclics LLC"
      },
      {
        "name": "Bendamustine hydrochloride",
        "doseForm": "Injection",
        "strength": "Not specified",
        "manufacturer": "Not specified"
      },
      {
        "name": "Rituximab",
        "doseForm": "Injection",
        "strength": "Not specified",
        "manufacturer": "Not specified"
      }
    ],
    "substances": [
      {
        "name": "Ibrutinib",
        "description": "1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d] pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one"
      },
      {
        "name": "Bendamustine hydrochloride",
        "description": "Mechlorethamine derivative"
      },
      {
        "name": "Rituximab",
        "description": "Monoclonal antibody"
      }
    ],
    "administrations": [
      {
        "name": "Ibrutinib 560 mg daily",
        "dose": "560 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Daily and continuously until disease progression or unacceptable toxicity"
      },
      {
        "name": "Bendamustine 90 mg/m2",
        "dose": "90 mg/m2",
        "frequency": "Days 1 and 2 of each 28-day cycle",
        "route": "Intravenous",
        "duration": "Maximum of 6 cycles"
      },
      {
        "name": "Rituximab Induction",
        "dose": "375 mg/m2",
        "frequency": "Day 1 of each 28-day cycle",
        "route": "Intravenous",
        "duration": "Cycles 1 to 6"
      },
      {
        "name": "Rituximab Maintenance",
        "dose": "375 mg/m2",
        "frequency": "Day 1 of every second cycle (even cycles)",
        "route": "Intravenous",
        "duration": "Maximum of 12 additional doses (up to Cycle 30)"
      },
      {
        "name": "Ibrutinib Dose Reduction (Strong CYP3A Inhibitor)",
        "dose": "140 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Duration of strong CYP3A inhibitor use"
      }
    ],
    "devices": []
  }
}